Lianhua Qingwen Prescription for Coronavirus Disease 2019 (COVID-19) Treatment: Advances and Prospects

Overview

Journal Biomed Pharmacother

Specialties Biology
General Medicine
Pharmacology

Date 2021 Jul 29

PMID 34321172

Citations 30

Authors

Liu-Cheng Li

Zhi-Hui Zhang

Wen-Cheng Zhou

Jie Chen

Hua-Qian Jin

Hong-Mei Fang

Qin Chen

Ye-Cheng Jin

Jiao Qu

Lian-Di Kan

Affiliations

Soon will be listed here.

Abstract

Background: An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. Though no specific drug has been developed so far, emerging agents have been confirmed effective or potentially beneficial to restrain it. Lianhua Qingwen (LHQW) is a commonly used Chinese medical preparation to treat viral influenza, including in the fight against SARS in 2002-2003 in China. Recent data also showed that LHQW played a vigorous role in COVID-19 treatment.

Purpose: This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19.

Study Design And Method: The research data were obtained from the academic databases (up to August 8, 2020) including Pubmed, CNKI and Web of Science, on ethnobotany and ethno medicines. The search keywords for screening the literature information were "virus", "COVID-19", or "SARS-CoV-2", and "Lianhua Qingwen". The documents were filtered and summarized for final evaluation.

Results: The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. Impressively, LHQW in conjunction with conventional treatment could significantly improve COVID-19 patients as a synergetic strategy. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function.

Conclusion: Although the data were far from adequate, the latest advances had shown the benefits of LHQW in COVID-19, especially in combination with other antiviral drugs. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. Nevertheless, imperious researches should be conducted to clarify the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19 by means of well designed randomized controlled trials.

Citing Articles

Efficacy of Kegan Liyan oral liquid vs. Lianhuaqingwen capsules for patients with mild COVID-19: a double-blinded, randomized, controlled, non-inferiority trial.

Li Y, Chi Y, Zhu M, Fan F, Deng Z, Xiao J Front Med (Lausanne). 2025; 12:1531370.

PMID: 40078399 PMC: 11896872. DOI: 10.3389/fmed.2025.1531370.

Impact of Lianhua Qingwen on viral shedding in omicron mild/asymtomatic patients: a real-world study.

Gai X, Yan C, Wu C, Duan Z, Fan J, Yuan S Front Med (Lausanne). 2024; 11:1357299.

PMID: 38596791 PMC: 11002109. DOI: 10.3389/fmed.2024.1357299.

The role of pyroptosis in viral infection.

Zhao Z, Zhang Y, Luo B Arch Virol. 2024; 169(3):69.

PMID: 38456965 DOI: 10.1007/s00705-024-05978-9.

Network pharmacology-based exploration identified the antiviral efficacy of Quercetin isolated from mulberry leaves against enterovirus 71 via the NF-κB signaling pathway.

Liu T, Li Y, Wang L, Zhang X, Zhang Y, Gai X Front Pharmacol. 2023; 14:1260288.

PMID: 37795035 PMC: 10546324. DOI: 10.3389/fphar.2023.1260288.

Combination of Chinese herbal medicine and conventional western medicine for coronavirus disease 2019: a systematic review and meta-analysis.

Tong L, Ma Z, Zhou Y, Yang S, Yang Y, Luo J Front Med (Lausanne). 2023; 10:1175827.

PMID: 37529247 PMC: 10387529. DOI: 10.3389/fmed.2023.1175827.

References

Tian S, Song X, Wang Y, Wang X, Mou Y, Chen Q . Chinese herbal medicine Baoyuan Jiedu decoction inhibits the accumulation of myeloid derived suppressor cells in pre-metastatic niche of lung via TGF-β/CCL9 pathway. Biomed Pharmacother. 2020; 129:110380. DOI: 10.1016/j.biopha.2020.110380. View

Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S . Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020; 156:104761. PMC: 7102548. DOI: 10.1016/j.phrs.2020.104761. View

Lu Z, Wu L, Mou Y, Duan H, Chen R, Xiao Y . [Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia]. Zhongguo Zhong Yao Za Zhi. 2021; 46(4):1000-1009. DOI: 10.19540/j.cnki.cjcmm.20200508.501. View

Ping F, Li Z, Zhang F, Li D, Han S . Effects of Lianhua Qingwen on Pulmonary Oxidative Lesions Induced by Fine Particulates (PM2.5) in Rats. Chin Med Sci J. 2017; 31(4):233-8. DOI: 10.1016/s1001-9294(17)30006-8. View

Hu K, Guan W, Bi Y, Zhang W, Li L, Zhang B . Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine. 2021; 85:153242. PMC: 7229744. DOI: 10.1016/j.phymed.2020.153242. View

Ma Y, Zhang Z, Wei L, He S, Deng X, Ji A . Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial. J Tradit Chin Med. 2018; 37(2):185-92. PMC: 7147198. DOI: 10.1016/s0254-6272(17)30043-2. View

Chen J, Wang Y, Gao Y, Hu L, Yang J, Wang J . Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Biomed Pharmacother. 2020; 129:110281. PMC: 7247521. DOI: 10.1016/j.biopha.2020.110281. View

Wang X, Ding Y . [From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment]. Zhonghua Bing Li Xue Za Zhi. 2020; 49(6):647-652. DOI: 10.3760/cma.j.cn112151-20200318-00220. View

Zhao P, Yang H, Lv H, Wei Z . Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. Altern Ther Health Med. 2014; 20(2):25-30. View

10.

Wang S, Liu J, Zhang Y, Dong Z . [Systematic review of efficacy and safety of Lianhua Qingwen Capsules in treatment of viral influenza]. Zhongguo Zhong Yao Za Zhi. 2019; 44(7):1503-1508. DOI: 10.19540/j.cnki.cjcmm.20190102.001. View

11.

Kong Q, Wu Y, Gu Y, Lv Q, Qi F, Gong S . Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Biomed Pharmacother. 2020; 128:110316. PMC: 7260557. DOI: 10.1016/j.biopha.2020.110316. View

12.

Yang C, Wang Y, He J, Yan W, Jiang H, Chen Q . Lianhua-Qingwen Displays Antiviral and Anti-Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model. Evid Based Complement Alternat Med. 2020; 2020:3196375. PMC: 7293728. DOI: 10.1155/2020/3196375. View

13.

Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

14.

Batlle D, Wysocki J, Satchell K . Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. Clin Sci (Lond). 2020; 134(5):543-545. DOI: 10.1042/CS20200163. View

15.

Duan Z, Jia Z, Zhang J, Liu S, Chen Y, Liang L . Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl). 2011; 124(18):2925-33. View

16.

Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q . The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017; 17(1):130. PMC: 5324200. DOI: 10.1186/s12906-017-1585-7. View

17.

Wang Z, Chen X, Lu Y, Chen F, Zhang W . Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020; 14(1):64-68. DOI: 10.5582/bst.2020.01030. View

18.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

19.

Ren Y, Yao M, Huo X, Gu Y, Zhu W, Qiao Y . [Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway]. Zhongguo Zhong Yao Za Zhi. 2020; 45(6):1225-1231. DOI: 10.19540/j.cnki.cjcmm.20200224.405. View

20.

Gao D, Niu M, Wei S, Zhang C, Zhou Y, Yang Z . Identification of a Pharmacological Biomarker for the Bioassay-Based Quality Control of a Thirteen-Component TCM Formula (Lianhua Qingwen) Used in Treating Influenza A Virus (H1N1) Infection. Front Pharmacol. 2020; 11:746. PMC: 7261828. DOI: 10.3389/fphar.2020.00746. View